PETALUMA, Calif., May 08, 2018 (GLOBE NEWSWIRE) -- Sonoma Pharmaceuticals, Inc. (Nasdaq:SNOA), a specialty
pharmaceutical company that develops and markets unique and effective dermatological solutions, announced today that Marc
Umscheid has been promoted to chief operating officer effective immediately.
“Since joining Sonoma in January of last year after a 17-year career at the Clorox Company, Marc has added significant value to
our strategic thinking, brand-building, innovation and digital marketing efforts,” says Jim Schutz, CEO. “We look forward to
Marc taking on an expanded role while helping us grow profitably.”
Umscheid is a graduate of Cornell University, where he received both a BS in business management/finance and an MBA from the
Johnson Graduate School of Management.
About Sonoma Pharmaceuticals, Inc.
Sonoma is a specialty pharmaceutical company that develops and markets unique and effective solutions for the treatment of
dermatological conditions and advanced tissue care. The company’s products, sold throughout the United States and internationally,
have improved outcomes for more than five million patients globally by reducing infections, itch, pain, scarring and harmful
inflammatory responses. The company's headquarters are in Petaluma, California, with manufacturing operations in the United
States and Latin America. European marketing and sales are headquartered in Roermond, Netherlands. More information can be
found at www.sonomapharma.com.
Forward-Looking Statements
Except for historical information herein, matters set forth in this press release are forward-looking within the meaning of
the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995, including statements about the commercial and
technology progress and future financial performance of Sonoma Pharmaceuticals, Inc. and its subsidiaries (the “Company”).
These forward-looking statements are identified by the use of words such as “believe,” “taking on,” and “grow,” among others.
Forward-looking statements in this press release are subject to certain risks and uncertainties inherent in the Company’s business
that could cause actual results to vary, including such risks that regulatory clinical and guideline developments
may change, scientific data may not be sufficient to meet regulatory standards or receipt of required regulatory clearances or
approvals, clinical results may not be replicated in actual patient settings, protection offered by the
Company’s patents and patent applications may be challenged, invalidated or circumvented by its competitors, the
available market for the Company’s products will not be as large as expected, the Company’s products will not
be able to penetrate one or more targeted markets, revenues will not be sufficient to fund further development and clinical
studies, as well as uncertainties relative to varying product formulations and a multitude of diverse regulatory and
marketing requirements in different countries and municipalities, and other risks detailed from time to time in the Company’s
filings with the Securities and Exchange Commission. The Company disclaims any obligation to update these forward-looking
statements, except as required by law.
Sonoma Pharmaceuticals is a registered trademark of Sonoma Pharmaceuticals, Inc. All other trademarks and service marks are the
property of their respective owners.
Media and Investor Contact:
Sonoma Pharmaceuticals, Inc.
Bob Miller
CFO
(925) 787-6218
